Flagging what CEO Douglas Onsi called the “difficult market environment,” immune specialist Leap Therapeutics will lay off approximately half of its workforce. The biotech made the announcement alongside its first-quarter 2025 earnings report, where it posted a net loss of $15.4 million, falling further into the red compared to the same period in 2024, during which it was operating with a $13.8 million deficit. Leap pointed to heightened R&D expenses as the reason for the increase in its loss.
